SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Addres	1 0	on*	2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
<u>Johnson Josep</u>	<u>)n</u>				Director	10% Owner							
					Officer (give title below)	Other (specify below)							
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		,	,							
C/O NABI BIOP	HARMACEUTI	CALS	02/24/2006		Sr. VP, HR, IT, Bı	is. Strat.							
5800 PARK OF (COMMERCE BL	VD., N.W.											
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing	(Check Applicable							
(Street)					Form filed by One Dane	ting Deveen							
BOCA RATON	FL	33487		X	Form filed by One Repo	rting Person							
,					Form filed by More than Person	One Reporting							
(City)	(State)	(Zip)											

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			4. Securities A Disposed Of (I 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	02/24/2006	Α		32,637(1)	Α	\$ <mark>0</mark>	32,637	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$3.83	02/24/2006		A		46,849		03/01/2009	02/24/2016	Common Stock	46,849	\$0	46,849	D	

Explanation of Responses:

1. Restricted stock that vests on March 1, 2009.

Remarks:

<u>/s/ James E. Dawson, as</u> attorney-in-fact

02/28/2006

** Signature of Reporting Person Da

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.